DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Sweden
  • /
  • Healthcare
Author Program NEWCreate Narrative
SUS logo

Surgical Science Sweden AB (publ) Stock Price

OM:SUS Community·SEK 2.6b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 25 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

SUS Share Price Performance

SEK 0
-91.50 (-100.00%)
​
SEK 59.80
Fair Value
SEK 0
-91.50 (-100.00%)
​
Price SEK 0
Tue, 23 Jun 26
Fair ValueSEK 59.80
Share Pricen/a

SUS Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value SEK 59.8 16.5% undervalued intrinsic discount

Surgical And Robotic Simulation Will Improve Patient Safety

0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value SEK 59 15.3% undervalued intrinsic discount

Delayed Procurement And OEM Reliance Will Test Margins But Improve

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value SEK 88 43.2% undervalued intrinsic discount

Digital Health Simulation Will Transform Global Surgical Training

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
SUS logo
Surgical Science Sweden
15.3% undervalued intrinsic discount

Delayed Procurement And OEM Reliance Will Test Margins But Improve

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 21 Aug
Read Narrative
SUS logo
Surgical Science Sweden
16.5% undervalued intrinsic discount

Surgical And Robotic Simulation Will Improve Patient Safety

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 23 Jun
Read Narrative
SUS logo
Surgical Science Sweden
43.2% undervalued intrinsic discount

Digital Health Simulation Will Transform Global Surgical Training

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 21 May
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystLowTarget
SUS logo

SUS: Future Returns Will Reflect Improving Margins And Priced For Failure Shares

Fair Value: SEK 59 15.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
SUS logo

SUS: Organic Expansion Will Support Sector Leadership As Profitability Assumptions Are Refined

Fair Value: SEK 59.8 16.5% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
SUS logo

SUS: Earnings Power And Margin Outlook Will Support Undervalued Upside Potential

Fair Value: SEK 88 43.2% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

1 Risk
3 Rewards
View Full Analysis

Surgical Science Sweden AB (publ) Key Details

SEK 1.0b

Revenue

SEK 342.6m

Cost of Revenue

SEK 679.9m

Gross Profit

SEK 586.8m

Other Expenses

SEK 93.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 12, 2026
1.83
66.50%
9.11%
0.06%
View Full Analysis

About SUS

Founded
1997
Employees
319
CEO
Tom Englund
WebsiteView website
www.surgicalscience.com

Surgical Science Sweden AB (publ) develops and markets virtual reality simulators and customized training solutions for evidence-based medical training in Europe, North and South America, Asia, and internationally. The company offers Angio Mentor simulator for endovascular training; BRONCH Express, a portable version of BRONCH mentor simulator; ARTHRO Mentor for arthroscopic surgery skills acquisition; BRONCH Mentor, a simulator for optimizing bronchoscopy training; GI Mentor, a simulator for GI Endoscopy; HYST Mentor for True-To-Life diagnostic and therapeutic hysteroscopy training; URO Mentor, a virtual reality simulator for endourology training; EndoSim, a realistic scope simulator; FlexVR, a flexible and portable training platform which is designed to teach basic and advanced skills for robotic surgery; and LAP Mentor provides a wide array of laparoscopic training cases. It also provides LapSim training system comprising LapSim Haptic simulator that provides laparoscopic training; LapSim essence, a portable and ready-to-use VR simulator; and LapSim 360, which provides a high-immersion virtual reality training experience; MentorLearn, an end-to-end educational platform that makes simulation course management; and LapSim ST, a training system that prepares students for the operating room. In addition, the company offers PELVIC Mentor simulator provides anatomy and pelvic exam training; Perc Mentor suite for image-guided interventions; RobotiX Mentor for practice the motor and cognitive skills for surgeons; Simball Box, which combines with digitally collected metrics into a training tool; Spine Mentor, a training simulator for minimal invasive spine surgery; TEE Express, designed to teach Trans-Esophageal Echocardiography procedure using a TEE probe; TraumaVR, an ultimate mix of manikin and VR simulation; and Ultrasound Mentor for ultrasound training with multiple medical specialties. Surgical Science AB was founded in 1997 and is based in Gothenburg, Sweden.

Recent SUS News & Updates

Recent updates

No updates

Surgical Science Sweden AB (publ) Competitors

GETI B logo

Getinge

Symbol: OM:GETI B
Market cap: SEK 63.8b
SECT B logo

Sectra

Symbol: OM:SECT B
Market cap: SEK 55.1b
MCOV B logo

Medicover

Symbol: OM:MCOV B
Market cap: SEK 35.5b
ASKER logo

Asker Healthcare Group

Symbol: OM:ASKER
Market cap: SEK 22.6b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide